The FDA has approved Precedex (dexmedetomidine) for sedation of children aged 1 month to less than 18 years during non-invasive procedures like scans or minor exams. Precedex is already used in adults for sedation in the ICU and during procedures. This new approval expands its use to younger patients. The drug works by calming the brain without causing significant breathing problems, which is a key benefit for children. The approval is based on studies showing it is safe and effective for this age group. However, dosing is different for younger children (1 month to under 2 years) compared to older children (2 to under 18 years). Doctors will give a loading dose followed by a maintenance infusion. This approval gives healthcare providers another tool to help children stay calm and comfortable during medical procedures. It does not mean that every child needs this drug. Your child's doctor will decide if Precedex is right based on their health and the procedure. Always talk to your child's doctor about the risks and benefits of any sedation medicine.
FDA approved Precedex (dexmedetomidine) for Pediatric Procedural SedationFDA approved Precedex for sedation in children during procedures.
AI-generated summary of the cited source, checked by automated accuracy review. How we work
The FDA has approved Precedex (dexmedetomidine) for sedation of non-intubated pediatric patients aged 1 month to less than 18 years during non-invasive procedures. This new indication adds to the drug's existing approvals for adult intensive care unit sedation and procedural sedation. Precedex is an alpha-2 adrenergic receptor agonist that provides sedation without significant respiratory depression, making it a useful option for pediatric procedural sedation. The approval is based on clinical data demonstrating efficacy and safety in this population, though specific trial outcomes are not detailed in the label. Clinicians should note that dosing differs by age group, with a loading infusion of 1.5 mcg/kg for patients 1 month to less than 2 years and 2 mcg/kg for those 2 to less than 18 years, followed by a maintenance infusion titrated to effect.
＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)
Precedex is an alpha-2 adrenergic receptor agonist.
Precedex is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting (continuous infusion not to exceed 24 hours). It is also indicated for sedation of non-intubated adult patients prior to and/or during surgical and other procedures. Additionally, Precedex is indicated for sedation of non-intubated pediatric patients aged 1 month to less than 18 years prior to and during non-invasive procedures.
Dosing should be individualized and titrated to desired clinical effect. Administer using a controlled infusion device. For adult ICU sedation: loading infusion of 1 mcg/kg over 10 minutes, then maintenance infusion of 0.2 to 0.7 mcg/kg/hour. For adult procedural sedation: loading infusion of 1 mcg/kg over 10 minutes (0.5 mcg/kg for less invasive procedures or patients over 65), then maintenance infusion initiated at 0.6 mcg/kg/hour and titrated (range 0.2 to 1 mcg/kg/hour). For pediatric procedural sedation (1 month to <2 years): loading infusion of 1.5 mcg/kg over 10 minutes, then maintenance infusion of 1.5 mcg/kg/hour (range 0.5 to 1.5 mcg/kg/hour). For pediatric procedural sedation (2 to <18 years): loading infusion of 2 mcg/kg over 10 minutes, then maintenance infusion of 1.5 mcg/kg/hour (range 0.5 to 1.5 mcg/kg/hour). Consider dose reduction in patients over 65 years and those with impaired hepatic function.
Not reported in label.
Not reported in label.
Precedex provides sedation with minimal respiratory depression, making it a valuable option for procedural sedation in both adults and pediatric patients. Its use in the ICU is limited to 24 hours of continuous infusion.
More on dexmedetomidine
View Original Abstract ↓
Sedative-hypnotic use associated with OR 1.29 for incident Alzheimer's Disease
Meta-analysis links sedative-hypnotic drug use to higher Alzheimer risk
Related in Neurology
From Other Specialties
